Issue link: https://www.e-digitaleditions.com/i/1373953
62 Pharmaceutical Technology BIOLOGICS AND STERILE DRUG MANUFACTURING EBOOK 2021 P h a r mTe c h . c o m capacities. We are very grateful that through the support of the French government as well as all local institutions, we can now continue to deliver on this mission with the construction of Europe's first J.POD facility, this is critical for society." Acquisition Wu X i Biolog ics has entered i nto a n equ it y agreement w it h Pf izer China to acquire its biologics manufacturing facilities and labor force in Hangzhou, China (6). The 50,000-m 2 facilities feature drug substance (DS) capacities, which include 2 x 2000-L single-use bioreactors expandable to 4 x 2000-L (MFG20) and drug product (DP) capacities of vial filling (DP9) and pre-filled syringe (DP10). The transaction is set to close during the first half of 2021 and is expected to enhance DS and DP capabilities for WuXi. "We are pleased to work with Pfizer and add the new Hangzhou biologics manufacturing facilities to our global network to address the surging manufacturing demands for late-stage and commercial projects due to the success of our Win-the-Molecule strategy," said Chris Chen, CEO of WuXi Biologics, in a press release. "Globally DS and especially DP capacities are in urgent need now. The acquisition will allow us to better enable our global partners to develop and manufacture premier-quality biologics to benefit patients around the world." References 1. Catalent, "Catalent Biologics Completes Madison Facility Ex- pansion to Double Clinical and Commercial Drug Substance Capacity," Press Release, April 13, 2021. 2. Thermo Fisher Scientific, "Thermo Fisher Scientific Invest- ments Support Rapidly Increasing Bioprocessing Production," Press Release, March 10, 2021. 3. Fujifilm Diosynth Biotechnologies, "Fujifilm Diosynth Biotech- nologies Breaks Ground for Major Expansion of its Large Scale Biologics Production Facility in Denmark," Press Release, March 3, 2021. 4. Abzena, "Abzena Announces Location of New Biologics GMP Manufacturing Site With up to 12 X 2000L Bioreactors," Press Release, April 15, 2021. 5. Evotec, "Evotec Accelerates Access to Biologic Therapeutics With Initiation of Manufacturing Facility in Toulouse," Press Release, April 20, 2021. 6. WuXi Biologics, "WuXi Biologics to Acquire Biologics DS and DP Manufacturing Facilities from Pfizer China," Press Release, March 17, 2021. PT AbbVie, Inc. ........................................................................................ 27 BAXTER ................................................................................................. 9 Catalent Pharma Solutions .................................................................. 2 DASGIP GmbH .................................................................................... 25 Emergent BioSolutions .......................................................................13 Lighthouse Instruments .................................................................... 39 MARKEN...............................................................................................19 PDA ..................................................................................................... 63 Pharmaceutics International Inc. (Pii) ............................................... 45 PTI ........................................................................................................51 Renishaw .............................................................................................59 Rigaku Americas Holding Inc............................................................. 23 Thermo Fisher Scientific; Pharma Services ............................................................................. 33 University of Iowa Pharmaceuticals .................................................... CoverTip, 15 Veltek Associates, Inc .......................................................................... 7 Ad Index COMPANY PAGE COMPANY PAGE Operations